<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646984</url>
  </required_header>
  <id_info>
    <org_study_id>TARV-DEM-LD</org_study_id>
    <secondary_id>AEM 01-0480</secondary_id>
    <nct_id>NCT00646984</nct_id>
  </id_info>
  <brief_title>Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy</brief_title>
  <official_title>Comparison of Strategies of Interruption/Reinitiation of Antiretroviral Therapy in Response to Immunologic/Virologic Changes in HIV-Infected Patients With Lipodystrophy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To assess the safety on the progression of HIV infection and the efficacy on the
      evolution of metabolic parameters and body fat of either viral load- or CD4 cell-driven
      strategies of intermittent treatment in chronically HIV-1-infected persons.

      Design: Pilot, prospective, open, randomized, controlled 3-year study.

      Setting and patients: University hospital. Patients with viral load &lt;200 copies/mL and CD4
      cell count &gt;450/mm3 for at least the last 3 months. Three arms with 50 patients each, that
      will be randomized either to continue antiretroviral therapy, or to discontinue it as long as
      either HIV-1 RNA be lower than 30000 copies/mL or CD4 cell count be higher than 300/mm3.

      Study end-points: evolution of plasma metabolic parameters, body fat, and bone mineral
      density; incidence of adverse effects due to antiretroviral therapy and symptoms consistent
      with acute retroviral syndrome; incidence of virological failure (plasma HIV-1 RNA &gt;200
      copies/mL while on therapy), immunological failure (CD4 cell count &lt;200/mm3 while on
      therapy), or clinical failure (development of AIDS-defining illnesses); cost of
      antiretroviral therapy administered and time free of therapy in the arms assigned to
      intermittent treatment; and the evolution of T lymphocyte subpopulations and the development
      of proliferative and cytotoxic responses against HIV.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Limb fat content measured by dual X-ray absorptiometry</measure>
    <time_frame>96 weekks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other body composition analyses</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>HIV-Associated Lipodystrophy Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard continuous antiretroviral therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD-4 guided interruption arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Viral load driven treatment interruption</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard continuous antiretroviral therapy</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD-4 guided therapy interruption</intervention_name>
    <description>Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viral load driven treatment interruption</intervention_name>
    <description>Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected patients

          -  On stable antiretroviral therapy

          -  Viral load below 200 copies/ml

          -  CD4 above 450 cells/mcl during last 3 months

        Exclusion Criteria:

          -  Weight variation higher than 10% compared with previous stable weight

          -  Active (CDC-C) opportunistic events

          -  Major depression or schizophrenia under psychiatric treatment

          -  Lack of clinical stability

          -  Pregnant women or planning pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose M Gatell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2008</study_first_posted>
  <last_update_submitted>March 28, 2008</last_update_submitted>
  <last_update_submitted_qc>March 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>Esteban Martinez</name_title>
    <organization>Hospital Clinic of Barcelona</organization>
  </responsible_party>
  <keyword>Lipodystrophy</keyword>
  <keyword>Treatment interruption</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>HIV-Associated Lipodystrophy Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

